The Bcr-Abl inhibitor imatinib mesylate induces complete hematologic and cytogenetic remissions in most newly diagnosed chronic myeloid leukemia (CML) patients, but relatively few of them achieve molecular remission. In addition, imatinib is much less effective in advanced phase-CML as well as in Philadelphia-positive (Ph þ ) acute lymphoblastic leukemia (ALL), mainly due to the development of drug resistance. The challenge for the future is to improve current clinical results with kinase inhibitors in CML, developing strategies that can eradicate residual disease and overcome or prevent resistance. 'Dual' Src and Abl kinase inhibitors are an attractive class of compounds, since (a) these molecules are able to bind Bcr-Abl with less stringent conformational requirements with respect to imatinib, therefore allowing for efficient inhibition of several, resistance-associated mutant forms of Bcr-Abl; (b) Src kinases have been shown to be involved in Bcr-Abl-mediated leukemogenesis as well as upregulated in some patients resistant to imatinib. Here, we review the development, the mode of action and the preclinical or early clinical evaluation of several novel dual Src and Abl kinase inhibitors.
Introduction
The deregulated tyrosine kinase activity of the Bcr-Abl chimeric protein, resulting from the t(9;22)(q34;q11) chromosomal translocation 1 on the 22q-derivative -most commonly referred to as the Philadelphia (Ph) chromosome 2 -is essential for initiation and maintenance of 95% of chronic myeloid leukemias (CML) and 20% of acute lymphoblastic leukemias (ALL). This has made the Abl kinase an attractive target for therapeutic intervention. The introduction of imatinib mesylate (formerly STI571; Gleevect or Glivec s ) to the therapeutic armamentarium has changed the current management of CML. Imatinib is a small-molecule inhibitor of the Bcr-Abl tyrosine kinase, as well as of a limited number of other kinases (ABL, c-kit, PDGFRa and b, ARG and c-fms). [3] [4] [5] [6] [7] With imatinib therapy, a complete cytogenetic response has been reported in 50-60% of patients in chronic phase (CP) after interferon-a (IFN-a) failure; [8] [9] [10] 11 Imatinib is also effective in patients with CML in transformation. A hematologic response was achieved in approximately 80% of patients in accelerated phase (AP); 45% of them also achieved a major cytogenetic response (Silver et al. Blood 2004; 104: 23; abstract). 10, 12 In blast crisis (BC), 30% of patients achieved a hematologic response, but in only 15% of them this was complete (Silver et al. Blood 2004; 104: 23; abstract). 10 Despite these excellent results, there is still a need to improve therapy in CML. There are two major obstacles to imatinib-based therapies for patients with CML and Philadelphia-positive (Ph þ ) ALL. One is the persistence of Bcr-Ablpositive cells -this is known as 'residual disease' and can be detected by sensitive assays like nested reverse transcriptionpolymerase chain reaction (RT-PCR). The other major problem is relapse of the disease due to the emergence of resistance to imatinib. While responses in CP-CML patients have been shown to last more than 3 years, most responding patients with AP-and BC-CML and Ph þ ALL relapse early despite continued therapy.
The fact that resistance to imatinib is most commonly associated with reactivation of Bcr-Abl further demonstrates the importance of Bcr-Abl kinase activity in the pathogenesis of CML. On the other hand, the persistence of Bcr-Abl-positive cells in patients on imatinib therapy indicates that inhibition of the Abl kinase activity alone might not be sufficient to eradicate the leukemic cells.
Second-generation kinase inhibitors
Several second-generation kinase inhibitors have been synthesized and some of them are now in preclinical or in early stages of clinical assessment. Ideal attributes of novel inhibitors that may help in eradicating residual disease and reducing the incidence of resistance include:
(1) more potent Abl inhibition -which may more effectively reduce the leukemic cell mass from which mutant clones emerge; (2) inhibition of a broader range of kinases -which may provide additional growth inhibition through other kinasedependent pathways; (3) more flexibility in binding to different Bcr-Abl conformations -which may reduce the number of mutations capable of impairing drug binding.
Rationale for the use of dual SRC and ABL inhibitors
Src kinases are involved in Bcr-Abl-mediated leukemogenesis and have been implicated in some cases in imatinib resistance. [13] [14] [15] The Src family includes nine structurally-related, cytoplasmic nonreceptor tyrosine kinases (Src, Fyn, Yes, Blk, Yrk, Fgr, Hck, Lck and Lyn), some of which are ubiquitous and some of which display a tissue-specific expression pattern. Src family kinases regulate multiple cellular events like proliferation, differentiation, survival, cytoskeletal organization, adhesion and migration as a consequence of their ability to couple with many diverse classes of cellular receptors and many distinct cellular targets (reviewed in 16 ). Multiple Bcr-Abl domains have been shown to interact with and activate Src kinases independently of Abl kinase activity, and studies with dominant-negative mutants and Src inhibitors suggest that Src kinases may contribute to the proliferation and survival of myeloid cell lines expressing Bcr-Abl in vitro. Hck and Lyn are expressed and activated in CML blast-crisis patients and their upregulation correlates with disease progression and resistance in cell lines and patients treated with imatinib. 14, 15, 17 Active Src kinases may in turn promote Bcr-Abl phosphorylation and interaction with growth factor receptor-bound protein 2 (Grb2). 18, 19 The NH 2 -terminal half (B530 residues) of c-Abl bears 42% identity to the Src family kinases (excluding the NH 2 -terminal unique domain) and shares a similar domain organization, containing two modular peptide binding units (the SH2 and SH3 domains) followed by a tyrosine kinase domain (Figure 1) . The catalytically active state of Abl closely resembles the active form of Src-family kinases and is often potently inhibited by ATPcompetitive molecules originally developed as Src inhibitors. 21, 22 Taken together, these observations raised the possibility that small-molecule inhibitors with dual activity either against Abl or against Src might prove effective in CML and Ph þ ALL patients resistant to imatinib. 
Dasatinib
Dasatinib (BMS-354825) is an orally bioavailable Abl kinase inhibitor with two-log increased potency relative to imatinib that retained activity against 14 imatinib-resistant Bcr-Abl mutants (M244V, G250E, Q252H/R, Y253F/H, E255K/V, F317L, M351T, E355G, F359V, H396R, F486S) in preclinical studies. 23 The only imatinib-resistant Bcr-Abl isoform that was clearly resistant to dasatinib was the T315I mutant, which retained kinase activity even in the presence of micromolar concentrations of the compound. Dasatinib prolonged survival of mice with BCR-ABL-driven disease and inhibited proliferation of Bcr-Abl-positive bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML. 23 Recently, a three-dimensional structure of Abl complexed with dasatinib was determined by X-ray crystallography. 24 Key features of the Abl-dasatinib complex are placement of the activation loop of Abl in an open conformation and three hydrogen bonds between the kinase and the inhibitor. A pair of hydrogen bonds is formed in the hinge region of the ATP-binding site between the 2-amino hydrogen of dasatinib and the carbonyl oxygen of Met318 and between the 3-nitrogen of the thiazole ring of dasatinib and the amide nitrogen of Met318. A hydrogen bond is Figure 1 Structural organization of Src family, Abl and Bcr-Abl kinases. The central, common core is composed of a Src-homology-3 (SH3) domain, a Src-homology-2 (SH2) domain and a tyrosine kinase domain. SH3 domains bind to proline-rich sequences, and SH2 domains bind to phosphorylated tyrosines in a sequence-specific context. The regions located upstream of the SH3 domain and downstream of the kinase domain are diverse. The amino terminus of Abl-family members consists of the 'Cap' region, which is present in different splice variants and is involved in kinase inhibition. By contrast, the amino terminus of Src-family kinases contains myristoyl and/or palmitoyl groups which anchor the protein to membranes. Unique to Abl and Bcr-Abl is a long carboxy-terminal extension, known as the last exon region, which contains protein-protein interaction sites and is responsible for the diverse subcellular localizations and various functions of the protein. The last exon region contains proline-rich (PXXP) motifs that function as binding sites for the SH3 domains of adaptor proteins such as Crk and Grb2; and binding sites for DNA, for actin, for the tumor-suppressor proteins p53 and retinoblastoma (Rb), among others. Moreover, the last exon region contains three nuclear localization signals and one nuclear export signal which allows c-Abl to shuttle between the nucleus and the cytoplasm (adapted from Hantschel and Superti-Furga 20 ).
Dual TKI in CML G Martinelli et al also formed between the hydroxyl oxygen of Thr315 and the amide nitrogen of dasatinib. A comparison with the imatinib-Abl complex 21 reveals that the central cores of dasatinib and imatinib occupy overlapping regions but that these two inhibitors extend in opposite directions. Interactions between P-loop and dasatinib seem to be less critical for binding of this novel inhibitor, in contrast to what was reported for imatinib. This may explain the observed in vitro efficacy of dasatinib against several mutant kinase forms. Molecular docking studies 25 showed that dasatinib is likely to bind the inactive form of Abl -as imatinib does -although requiring a lower conformational stringency, with the ability of binding more intermediate conformations than imatinib (Figure 3) . In contrast, the active conformation of Abl has been predicted not to be favorable for the binding of dasatinib. A recent saturation mutagenesis screening of Bcr-Abl 26 also found that the spectrum of mutations that would allow for dasatinib resistance is reduced compared with that of imatinib, 27, 28 and includes L248R, Q252H, E255K, V299L, T315I/A, F317V/L/I/S ( Table 1 ). All but two of the mutations causing resistance map to known dasatinib contact residues as shown by crystallographic studies. Some mutants were unique to dasatinib (V299L, T315A, F317V/ I/S), whereas others also conferred imatinib resistance (L248R, Q252H, E255K, T315I, F317L). 26 Interestingly, combination of imatinib and dasatinib reduced the number of resistant clones and limited the range of drug-resistant Bcr-Abl mutations. 6519; abstract). In all, 36 patients (31 resistant and five intolerant to imatinib) have been treated with total daily doses ranging from 15 to 180 mg. Mutations associated with imatinib resistance were identified in 27 patients. In all, 31 patients (86%) have had a complete hematologic response. Only two patients have had progression of their disease. Of 29 patients, 13 had cytogenetic improvement including five complete and four partial cytogenetic responses (ie major cytogenetic responses (MCgR) in 9/29 patients, 31%). Hematologic and cytogenetic responses have occurred regardless of mutation status, or whether the mutation was in the P-loop, catalytic or activation region, with the exception of one patient who progressed with expansion of the T315I clone. Responses are durable, and 33 of 36 patients remain on study for 1 þ to 13 þ months. Similarly to imatinib, dasatinib was well tolerated in all patients. Three patients had grade 4 thrombocytopenia and two patients had grade 4 neutropenia, all of which were reversible and easily managed with dose modification. One patient developed a duodenal ulcer possibly related to dasatinib. Pharmacodynamic studies demonstrated greater than 50% inhibition of phosphorylation of the BCR-ABL substrate CrkL and of the Src kinase Lyn. Dose escalation continues. Phase I clinical results of dasatinib in AP-and BC-CML patients and Ph þ ALL patients who had hematologic progression or intolerance while being treated with imatinib are also available (Sawyers et al. ASCO Meeting Abstracts 2005; 23: 6520; abstract). Eight AP-CML patients, 18 BC-CML patients and three Ph þ ALL patients were treated with total daily doses of 35-90 mg. Mutations associated with imatinib resistance were identified in 16 of 28 patients with mutation data. The hematologic response rates (complete þ partial) were 75% for AP, 76% (13/17) for BC and 100% for Ph þ ALL (2/2) patients. Responses were durable for 2 þ to 6 þ months in 19 patients. The MCgR rate in BC patients is 53%. Responses occurred in 15 patients with mutations. Four patients had primary resistanced documented after 2 months; two relapsed within 2-3 months after an initial response. The Figure 2 Chemical structures of the dual Src and Abl inhibitors reported in this review.
Dual TKI in CML G Martinelli et al T315I mutation was identified in four of the six resistant patients. Dasatinib has been well tolerated. Myelosuppression was observed, with grade 4 thrombocytopenia in eight patients. Grade 3/4 fluid retention (1) and tumor lysis syndrome (2) occurred in three patients. Dose escalation is continuing also in the setting of AP-and BC-CML patients. Phase II studies in CP-, AP-and BC-CML and Ph þ ALL are currently being initiated.
SKI-606
SKI-606 belongs to a novel class of compounds, 4-anilino-3-quinolinecarbonitrile Src and Abl kinase inhibitors. This compound inhibited Src in an enzyme assay with an IC 50 of 1.2 nM, inhibited anchorage-independent growth of Srctransformed fibroblasts with an IC 50 of 100 nM, and inhibited Src-dependent protein tyrosine phosphorylation at comparable or lower concentrations. 33 SKI-606 was later shown to be a potent antiproliferative and proapoptotic agent against three different Bcr-Abl-positive cell lines (KU812, MEG-01, K562). 34 SKI-606 ablated tyrosine phosphorylation of Bcr-Abl, and, when tested in an Abl enzymatic assay, showed an IC 50 of 1 nM. SKI-606 also inhibited phosphorylation of cellular proteins, including STAT5, at concentrations that inhibit proliferation in CML cells. Phosphorylation of the autoactivation site of the Src family kinases Lyn and/or Hck was also reduced by treatment with SKI-606. The apoptotic activity of SKI-606 against CML cells in culture was mirrored by its activity in vivo against CML xenografts. K562 tumors regressed in nude mice when SKI-606 was administered per os once a day over a 5-day period.
AP23464
AP23464, a novel 2,6,9-trisubstituted purine analog, has been reported to be another potent ATP-based inhibitor of Src and Abl kinases. 29 The drug was tested against the Bcr-Abl-expressing human K562 cell line, and was found to selectively inhibit proliferation, block cell cycle progression and promote apoptosis. These effects were accompanied by the elimination of cellular tyrosine phosphorylation of Bcr-Abl and its downstream signaling effectors STAT-5 and CrkL. AP23464 was also tested against Abl kinase domains carrying mutations that cause imatinib resistance. Biochemical assays with purified wild-type (WT) and mutant (Y253F, E255K, T315I, M351T, H396P) glutathione S transferase (GST) -Abl kinase fusion proteins demonstrated potent inhibition of Abl autophosphorylation and Abl-catalyzed peptide substrate phosphorylation. The only one exception was the Abl mutant T315I (Table 1 ). In cell-based assays, the inhibitor effectively blocked proliferation of Ba/F3 cells expressing either WT Bcr-Abl or five of the most common imatinib mesylate-resistant Bcr-Abl variants (Q252H, Y253F, E255K, M351T and H396P) observed in the clinical setting, but not the T315I mutant (Table 1) . Consistent with cell proliferation Dual TKI in CML G Martinelli et al results, Annexin V binding assays confirmed that AP23464 induced apoptosis of Ba/F3 cells expressing either WT Bcr-Abl or AP23464-sensitive Bcr-Abl variants. Similarly, immunoblot analysis showed that AP23464 reduced cellular tyrosine phosphorylation of WT Bcr-Abl and imatinib-resistant Bcr-Abl mutants except T315I. A 3D molecular model of AP23464 complexed to Abl kinase domain was also constructed. 29 Unlike imatinib, AP23464 is predicted to bind only to the ATP-binding active conformation of Abl. Hence, AP23464 binding is not predicted to require an induced-fit mechanism involving extensive conformational changes within the P-loop. The side chain of Abl kinase residue Thr-315 modulates access to the binding site. Consequently, AP23464 is unable to effectively bind Bcr-Abl mutant T315I since the bulkier Ile-315 effectively blocks access to AP23464 as well as it does to imatinib.
PD173955, PD180970 and PD166326
Several compounds belonging to the pyrido[2,3-d]pyrimidine class of ATP-competitive inhibitors have been recently described. 21, 22, 30, 31, [35] [36] [37] [38] [39] The crystal structure of Abl in complex with PD173955 -the first member of this class to be reportedand with imatinib showed that the mode of binding to Abl may differ between 2-phenylaminopyrimidine-type (imatinib) and pyrido [2,3-d] pyrimidine-type compounds. 21 Indeed, PD173955 can bind both the active and inactive conformations of the kinase due its smaller size as compared to imatinib (Figure 4) . 21 Although PD173955 contacts far fewer amino acid residues than does imatinib, 21 it inhibits the tyrosine kinase activity of Bcr-Abl at approximately 100-fold lower concentrations (IC 50 ¼ 1-2 nM) . 22 In the low nanomolar range, PD173955 Bcr-Abl mutants which have been reported in patients resistant to imatinib are indicated in bold. The remaining mutants listed in the table were recovered from saturation mutagenesis screenings for mutations conferring resistance to dasatinib 26 and PD166326. 31 As can be seen from IC 50 values, some mutant forms have been found to be resistant to dasatinib (ie, V299L; T315A; F317V/I/S) or PD166326 (ie, G250V; F317C/V) but not to imatinib.
induced accumulation of Bcr-Abl-positive cells in the G1 phase of the cell cycle and inhibited the growth of primary CD34 þ primitive progenitor cells from a patient with BC-CML. 22 Two structurally-related compounds, PD180970 and PD166326, were subsequently reported to have even greater potency. 22, 30, 35, 38 In in vitro kinase assays, PD180970 potently inhibited autophosphorylation of Bcr-Abl (IC 50 ¼ 5 nM) and the kinase activity of purified recombinant Abl tyrosine kinase (IC 50 ¼ 2.2 nM). 35 In K562 cells, PD180970 potently inhibited tyrosine phosphorylation of Bcr-Abl (IC 50 ¼ 170 nM) and of its substrates Gab2 and CrkL (IC 50 ¼ 80 nM), and induced apoptosis.
35 PD180970 was also shown to be active against some clinically relevant ABL mutations affecting the P-loop (Y253F, E255K) and activation loop (M351T) ( Table 1) . 30 In contrast, there was no activity towards the T315I mutant. Similar results were obtained with PD166326. 37, 38 Very recently, results of a cell-based screen for mutations conferring resistance to PD166326 have been reported. 31 Colonies resistant to PD166326 exhibited an overlapping but distinct pattern of kinase domain mutations as compared to imatinib-resistant patients. As with imatinib, T315I and mutations affecting the P-loop were the most frequent, having been observed in 32 and 42%, respectively, of colonies resistant to PD166326. However, all P-loop mutants were easily suppressed by moderate increases of dosage. This may prove a relevant advantage since P-loop mutations account for almost half of all mutations that have been detected in patients and have been associated to a worse outcome. 40, 41 Taken together, all these observations suggest that with the clinical application of pyrido-pyrimidines, mutations of P-loop and activation loop would occur less frequently or would easily be overcome. The pharmacokinetic, signal transduction, and antileukemic properties of PD166326 have been also characterized in mice with CML-like disease.
39
PD166326 rapidly inhibited Bcr-Abl kinase activity after a single oral dose, and demonstrated marked antileukemic activity in vivo. In all, 70% of PD166326-treated mice achieved a WBC less than 20 000/ml at necropsy, compared with only 8% of imatinib-treated animals. Further, two-thirds of PD166326-treated animals had complete resolution of splenomegaly, compared to none of the imatinib-treated animals. PD166326 also prolonged the survival of mice with imatinib-resistant CML induced by the Bcr-Abl mutants H396P and M351T.
PP1 and CGP76030
PP1 and CGP76030 are two compounds originally described as Src inhibitors. [42] [43] [44] These compounds were tested on cell lines Dual TKI in CML G Martinelli et al positive both for wild-type and mutant Bcr-Abl. Both inhibitors were shown to induce growth arrest and apoptosis in Bcr-Ablpositive 32D cells to a degree similar to imatinib mesylate. 45 Moreover, both compounds killed Bcr-Abl-positive cell lines derived from CML patients. A comparison of the binding of PP1, CGP76030 and imatinib mesylate to various Bcr-Abl mutants showed that these inhibitors had largely overlapping binding modes in that all of them were sensitive to amino acid substitutions at position 315. However, PP1 and CGP76030 still significantly reduced cell growth and survival of 32D cell lines expressing the Bcr-Abl T315 mutants, suggesting that both compounds could act by inhibiting additional kinase targets. In contrast to imatinib, both PP1 and CGP76030 were shown to bind and inhibit Bcr-Abl independently of the activation-loop conformation.
Another recent study showed that certain Src kinases (Lyn, Hck and Fgr) are necessary for the induction of B-cell acute lymphoblastic leukemia (B-ALL) but dispensable for the induction of CML in nude mice. 46 This evidence provides a rationale for the use of Src kinase inhibitors to treat also Ph þ B-ALL. In the same study, CGP76030 impaired the proliferation of B-lymphoid cells expressing Bcr-Abl in vitro and prolonged survival of mice with B-ALL but not CML. The combination of CGP76030 and imatinib was superior to imatinib alone in this regard. The biochemical targets of CGP76030 in those cells were demonstrated to be Src kinases and not Bcr-Abl. These results predict that (a) simultaneous inhibition of both Src and Bcr-Abl kinases with a dual inhibitor or with a 'combinatory' kinase inhibitor approach may benefit individuals with Ph þ acute leukemia, and (b) a dual Src and Abl inhibitor therapy in CP-CML may prove effective only in the case of an increased expression and activation of Src kinases associated with imatinib resistance.
Conclusions
Dual Src and Abl kinase inhibitors are attractive compounds allowing for (1) more potent Abl inhibition; (2) inhibition of Src kinases such as Lyn and Hck, which have been implicated both in Bcr-Abl-mediated leukemogenesis and in resistance to imatinib; (3) more flexibility in binding to different Bcr-Abl conformations, thereby reducing the number of mutations capable of impairing drug binding. While dasatinib is already entering phase I/II clinical trials, several additional promising molecules have demonstrated remarkable efficacy in preclinical models. It has been argued that the lower selectivity may negatively influence the toxicity profile of these agents. While Bcr-Abl is a pathogenetic target expressed by Ph þ cells only, Src family proteins also have their multiple and ubiquitous physiological functions and so can influence multiple cellular pathways simultaneously. On the other hand, short-term side effects of dasatinib in patients with a median follow-up of 4 months have been recently reported to be mild and generally manageable. However, as dasatinib and the other inhibitors discussed in this review are relatively new agents, only an extended follow-up may reveal unanticipated longer-term results.
